Zacks: Harrow Health (NASDAQ:HROW) Given Average Rating of “Strong Buy” by Analysts

Harrow Health (NASDAQ:HROW) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price target of $11.38 for the company and are forecasting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Harrow Health an industry rank of 83 out of 256 based on the ratings given to related companies.

Several equities research analysts have recently weighed in on the stock. ValuEngine raised shares of YPF from a “sell” rating to a “hold” rating in a research report on Monday, June 24th. Zacks Investment Research downgraded shares of HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, TheStreet downgraded shares of ZTO Express (Cayman) from a “b+” rating to a “c” rating in a research report on Wednesday, May 1st.

In other news, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $5.78, for a total value of $57,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert J. Kammer sold 6,500 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $7.91, for a total transaction of $51,415.00. The disclosure for this sale can be found here. Insiders sold a total of 26,500 shares of company stock valued at $154,915 in the last three months. Insiders own 12.43% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HROW. FineMark National Bank & Trust bought a new stake in shares of Harrow Health during the 1st quarter valued at about $113,000. EAM Global Investors LLC bought a new stake in shares of Harrow Health during the 1st quarter valued at about $171,000. Institutional & Family Asset Management LLC bought a new stake in shares of Harrow Health during the 1st quarter valued at about $195,000. Alambic Investment Management L.P. bought a new stake in shares of Harrow Health during the 1st quarter valued at about $252,000. Finally, Corrado Advisors LLC bought a new stake in shares of Harrow Health during the 2nd quarter valued at about $475,000. 32.08% of the stock is owned by institutional investors.

Harrow Health stock traded down $0.05 during midday trading on Friday, hitting $7.82. 174,671 shares of the stock were exchanged, compared to its average volume of 422,708. Harrow Health has a 1 year low of $2.22 and a 1 year high of $8.99. The stock has a market cap of $194.42 million, a price-to-earnings ratio of 12.82 and a beta of 0.05. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.22 and a current ratio of 3.43. The company has a 50 day simple moving average of $7.01.

Harrow Health (NASDAQ:HROW) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.14). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The firm had revenue of $12.29 million for the quarter, compared to analysts’ expectations of $12.10 million. On average, equities research analysts anticipate that Harrow Health will post -0.1 EPS for the current fiscal year.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Featured Story: What is the S&P 500 Index?

Get a free copy of the Zacks research report on Harrow Health (HROW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.